Understanding Cancer Patients' Preferences for Genetic Information Before Exome Analysis
Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis. Qualitative Observational and Interventional Cross-sectional Study
This study is trying to find out how cancer patients want to receive genetic information before they have a specific genetic test, to make sure they understand their treatment options better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Georges Francois Leclerc Academic / other |
| Locations | 2 sites (Dijon and 1 other locations) |
| Trial ID | NCT06550687 on ClinicalTrials.gov |
What this trial studies
This study investigates how cancer patients prefer to receive genetic information prior to undergoing theranostic exome analysis. It involves observing patient-physician communication during consultations and conducting interviews with patients to gather insights on their preferences. The study aims to enhance understanding of how information is conveyed and comprehended, ensuring that patients are well-informed about their treatment options. Participants will be drawn from the EXOMA2 patient file at Dijon University Hospital.
Who should consider this trial
Good fit: Ideal candidates include cancer patients who are part of the EXOMA2 study and are fluent in French.
Not a fit: Patients who have previously undergone oncogenetic consultations or those with cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve patient understanding and satisfaction regarding genetic information related to their cancer treatment.
How similar studies have performed: While this approach is innovative in its focus on patient preferences for genetic information, similar studies have shown the importance of effective communication in healthcare settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient identified for inclusion in the EXOMA 2 study (exome analysis request) * Available to receive different types of information * Fluent in French * No prior oncogenetic consultation * Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study * Authorizing audio recording of consultations and interviews Exclusion Criteria: * Patient who refused to participate in the EXOMA2 study (for phase 3 patients only) * Has a psychiatric, cognitive or neurological disorder that makes participation impossible * Working in the field of genetics
Where this trial is running
Dijon and 1 other locations
- Centre Georges-François Leclerc — Dijon, France (Recruiting)
- CHU François Mitterand — Dijon, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.